Jefferies raised the price target for the Verona Pharma Plc ADR (NASDAQ:VRNA) stock to “a Buy”. The rating was released on May 22, 2023, according to finviz. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $31. The stock was initiated by H.C. Wainwright, who disclosed in a research note on September 13, 2021, to Buy and set the price objective to $25. In their research brief published August 25, 2020, Jefferies analysts initiated the Verona Pharma Plc ADR stock to Buy with a price target of $17.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated 0.58% within the last five trades and -20.70% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -7.86% in the last 6 months and -33.64% was subtracted to its value over the previous 3 months. VRNA stock is trading at a margin of -11.06%, -19.65% and -25.18% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Sponsored
As of the close of trading, VRNA deals in the Healthcare domain. The stock is trading -47.68 percent below its 52-week high and 5.97 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -46.56. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Verona Pharma Plc ADR’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 0.00 percent and the company has reported a gross margin of -110.38 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $978.64 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 4.34, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 24.11 percent of Verona Pharma Plc ADR shares are owned by insiders, and 60.11 percent are held by financial institutions. Rickard Kathleen A., the Chief Medical Officer at Verona Pharma Plc ADR (VRNA) has sold 36,248 shares of firm on May 03 ’24 at a price of $1.96 against the total amount of $71032.0. In another inside trade, Rickard Kathleen A., Chief Medical Officer of Verona Pharma Plc ADR (NASDAQ:VRNA) sold 36,248 shares of the firm on Feb 05 ’24 for a total worth of $80503.0 at a price of $2.22. An inside trade which took place on Nov 20 ’23, Director of Verona Pharma Plc ADR Edwards Martin bought 33,736 shares of firm against total price of $61973.0 at the cost of $1.84 per share.
